UBS Group
MIST icon

UBS Group’s Milestone Pharmaceuticals MIST Stock Holding History

UBS Group’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Sell
465,403
-29,505
-6% -$47.2K ﹤0.01% 6090
2026
Q1 		$589K Buy
494,908
+3,040
+0.6% +$5.32K ﹤0.01% 5968
2025
Q4 		$994K Buy
491,868
+94,334
+24% +$203K ﹤0.01% 5582
2025
Q3 		$795K Buy
397,534
+74,886
+23% +$132K ﹤0.01% 5743
2025
Q2 		$626K Buy
322,648
+211,125
+189% +$282K ﹤0.01% 5835
2025
Q1 		$89.2K Buy
111,523
+22,017
+25% +$43.8K ﹤0.01% 7131
2024
Q4 		$211K Buy
+89,506
New +$154K ﹤0.01% 6416
2024
Q2 		– Sell
-2,618
Closed -$4.69K – 9880
2024
Q1 		$4.69K Buy
+2,618
New +$4.25K ﹤0.01% 7604
2023
Q4 		– Sell
-1,693
Closed -$5.25K – 9675
2023
Q3 		$5.25K Sell
1,693
-1,644
-49% -$5.11K ﹤0.01% 7384
2023
Q2 		$9.51K Buy
3,337
+565
+20% +$2.13K ﹤0.01% 7174
2023
Q1 		$10.9K Sell
2,772
-2,413
-47% -$8.82K ﹤0.01% 7541
2022
Q4 		$20.5K Buy
5,185
+1,865
+56% +$9.82K ﹤0.01% 7626
2022
Q3 		$31K Buy
3,320
+2,304
+227% +$17.5K ﹤0.01% 6836
2022
Q2 		$6K Buy
+1,016
New +$6.24K ﹤0.01% 8696
2022
Q1 		– Sell
-1,031
Closed -$7K – 10643
2021
Q4 		$7K Buy
+1,031
New +$6.17K ﹤0.01% 9155
2021
Q3 		– Sell
-483
Closed -$3K – 9861
2021
Q2 		$3K Sell
483
-13,016
-96% -$73.8K ﹤0.01% 8819
2021
Q1 		$78K Sell
13,499
-1,147
-8% -$8.39K ﹤0.01% 6154
2020
Q4 		$98K Sell
14,646
-1,914
-12% -$12.8K ﹤0.01% 5700
2020
Q3 		$121K Buy
16,560
+3,061
+23% +$21.9K ﹤0.01% 5079
2020
Q2 		$51K Hold
13,499
– – ﹤0.01% 5838
2020
Q1 		$25K Buy
+13,499
New +$234K ﹤0.01% 6350

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

UBS Group's MIST Position: Q2 2026 in Review

UBS Group reduced its Milestone Pharmaceuticals (MIST) stake by 6% in Q2 2026, selling an estimated $47.2K and leaving 465,403 shares worth $624K. The position accounts for ﹤0.01% of the portfolio, ranked #6090.

UBS Group first reported a position in MIST in Q1 2020 and has held it in 21 quarters since. The position peaked at $994K in Q4 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • UBS Group held 465,403 shares of Milestone Pharmaceuticals worth $624K as of Q2 2026.
  • UBS Group sold 29,505 Milestone Pharmaceuticals shares in Q2 2026, an estimated $47.2K.
  • Milestone Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6090 holding.
  • UBS Group first reported a position in Milestone Pharmaceuticals in Q1 2020 and has held it in 21 quarters since.
  • UBS Group's Milestone Pharmaceuticals position peaked at $994K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.